Long-term safety of admilparant in people with pulmonary fibrosis
Checks long-term safety of admilparant in people who finished earlier pulmonary fibrosis studies.
Plain-language title generated from the registry record
Registry title: Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Key facts
- Where
- Angers, Bobigny, Brest, Bron, Dijon, Grenoble Cedex 9, Marseille, Nice, Paris Cedex 18, Pessac, Saint-Herblain, and Toulouse, FranceSee the 12 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pulmonary fibrosis who took part in the earlier studies IM027068 (idiopathic pulmonary fibrosis) or IM0271015 (progressive pulmonary fibrosis). It tests the long-term safety of Admilparant.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Pulmonary fibrosis: idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). People must have taken part in the earlier study for their type.
- Earlier treatment
- People must have taken part in the earlier study IM027068 or IM0271015. They cannot have stopped treatment for good by withdrawing consent in that study.
Main reasons for not taking part
- Any disease or condition that the investigator thinks is an unacceptable safety risk
- Any side effect that led to permanent stop of the study drug in the earlier study
- Heart failure symptoms at rest
- History of lung reduction surgery or lung transplant
- Known pulmonary arterial hypertension (PAH) on single-drug therapy that now needs several drugs
Read by machine on 12 November 2026.
Where in France
- Centre Hospitalier Universitaire D'AngersAngers, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisBobigny, FranceNot yet recruiting
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceNot yet recruiting
- Hospices Civils de LyonBron, FranceNot yet recruiting
- Centre Hospitalier Universitaire de DijonDijon, FranceNot yet recruiting
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceNot yet recruiting
- Centre Hospitalier Regional De MarseilleMarseille, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NiceNice, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisParis Cedex 18, FranceNot yet recruiting
- Centre Hospitalier Universitaire de BordeauxPessac, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NantesSaint-Herblain, FranceNot yet recruiting
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07441408EU 2025-522373-10-00
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).Read full original descriptionShow less
An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Inclusion: Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015.
Exclusion: Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation; Exhibit symptoms of heart failure at rest; History of lung reduction surgery or lung transplant; Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy; Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015; Other protocol-defined Inclusion/Exclusion criteria apply.